재발된 혹은 불응성 비호지킨 림프종에서 고용량 항암요법과 표준 구출요법의 비교 = High Dose Therapy and Autologous Stem Cell Transplantation as Compared with Salvage Chemotherapy in Relapsed or Refractory Patients with Non-Hodgkin's Lymphoma

다국어 초록 (Multilingual Abstract)

Background: Patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) who have a relapse or refractoriness after initial standard chemotherapy generally have a poor prognosis. Conventional salvage treatment can induce lengthy remission. It is, however, not generally agreed that long-term survival has been expected in patients receiving salvage chemotherapy. The combination of high dose therapy and autologous stem cell transplantation has been considered promising in refractory or relapsed patients with NHL.
Methods: The response rate and survival (disease-free and overall survival) of 15 patients with relapsed or refractory NHL who only received salvage chemotherapy was compared with those of 14 patients who has been assigned to receive high dose therapy and autologous stem cell transplantation.
Results: the overall rate of response to salvage chemotherapy was 13% but that of high dose therapy with stem cell support was 58%.
Disease free survival (DFS) in the salvage chemotherapy group was very low; only 2 patients survived in remission without a relapse of disease in long duration. On the contrary the rate of DFS in the transplantation group was 48% at 3 years.
At 3 years, the rate of overall survival (OS) was 17% in the group receiving salvage chemotherapy and 31% in the transplantation group.
Conclusion: As compared with salvage chemotherapy, treatment with high dose therapy and autologous stem cell transplantation increases disease-free and overall survival in relapsed or refractory patients with non-Hodgkin's lymphoma.